Arrowhead Pharmaceuticals refinances $400 million loan with Sixth Street

• Arrowhead Pharmaceuticals refinanced its existing $400 million facility with a new $400 million senior secured term loan facility from Sixth Street-managed funds.
• The new loan carries annual interest of three-month SOFR plus 5.50%, replacing the retired facility’s 15% annual rate.
• The refinancing retired the existing facility at a $68 million discount to its contractual minimum repayment amount.
• Maturity extends to November 2, 2031, with all principal due at maturity and no scheduled amortization payments.
• The new facility eliminates mandatory prepayments from specified transaction proceeds, partnership payments and commercial revenue, improving liquidity flexibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104639267) on November 04, 2026, and is solely responsible for the information contained therein.